Browse studies

Find your next paid study

930 recruiting studies matching your filters

Newest first Highest paying

Phase 1

A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT05379985

Phase 1

A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this …

Solid TumoursSarcomaHNSCC+12 more

A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation

The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the s…

Solid Tumor Malignancies

Estimated

~$10 – $8,750

Kumquat Biosciences Inc.NCT07207707

Phase 1

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.

Solid Tumors

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06066424

Phase 1

Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and …

Solid Tumors With HRAS AlterationsNon Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)+4 more

Estimated

~$10 – $8,750

Kura Oncology, Inc.NCT06026410

Phase 1

A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AN9025 in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

The goal of this clinical trial is to learn determine if AN9025 is safe and tolerable to treat solid cancer tumors with specific genetic mutations. It will hel…

Solid Tumors (Phase 1)RAS Mutation

Estimated

~$10 – $8,750

Adlai Nortye Biopharma Co., Ltd.NCT07252479

Phase 1

Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-r…

Breast CancerEsophageal CancerKidney Cancer+15 more

Estimated

~$10 – $7,500

Brian Henick, MDNCT06673329

Phase 1

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT06040541

Phase 1

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants With Advanced/Metastatic Solid Tumors

A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors

Solid Tumor, Adult

Estimated

~$10 – $8,750

DualityBio Inc.NCT06554795

Observational

The Effect of Intraoperative Cortical Stimulation on Hand Strength and Function During Awake Craniotomies

The neurosurgical standard of care for treating a patient with a tumor invading hand primary motor cortex (M1) includes performing a craniotomy with intraopera…

Brain TumorBrain CancerMotor Cortex; Lesion

Estimated

~$10 – $6,250

Medical College of WisconsinNCT05023434

Phase 1

A Phase 1, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CS231295 in Patients With Advanced Solid Malignant Tumors

This is a Phase I, single-arm, open-label, dose-escalation, multicenter clinical study of CS231295 in patients with advanced solid malignant tumors. Eligible …

Advance Solid TumorsAdvanced Malignant Solid Tumors

Estimated

~$10 – $8,750

ThalassaX Therapeutics United States LtdNCT07612488

Phase 2

PHASE 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (GLOBOTRK)

This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other centr…

High Grade GliomaCNS Tumor

Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT06528691